By Deena Beasley (Reuters) - Guardant Health Inc on Thursday said a pivotal trial of its DNA blood test showed that it detected 83% of colorectal canc.
-Guardant Health Inc on Thursday said a pivotal trial of its DNA blood test showed that it detected 83% of colorectal cancers and 13% of advanced adenomas, a cancer precursor, but the results fell.